In the article “Precision medicine offers a glimmer of hope for Alzheimer's disease” Alzheimer's Disease" by Melissa Healy, indicates that twenty years of searching for effective ways to find a cure or prevent Alzheimer's disease have ended in failure. According to Healy, 5.7 million Americans have been seriously affected and cannot afford to survive this disease. This research focuses on a new experimental precision medicine study that has led to probable real-world results and hope for a treatment for Alzheimer's disease. Say no to plagiarism. Get a tailor-made essay on “Why Violent Video Games Should Not Be Banned”? Get the original essay The author primarily discusses the approach to research studies of the gathering of dementia specialists at the Alzheimer's Assn International Conference. in Chicago to assess the real hope both in precision medicine and in innovative clinical trial studies to be able to offer new treatments for brain diseases. The independent variable was the different existing stages of Alzheimer's disease in the patients. The dependent variable was the level of reduction in brain plaque in early cases of Alzheimer's disease, as opposed to a genetic substance typical of Alzheimer's disease, and 856 patients were included in these innovative clinical trials for the case study BAN2401. As for the case study, Anavex 2-73 was the patient's level of ability to reason, remember and carry out daily activities on his own. By examining 32 patients with mild to moderate Alzheimer's disease who had a genetic match for the substance to work successfully according to the researchers. The researcher's results demonstrated the effectiveness of precision medications in patients with Alzheimer's disease. Results from the BAN2401 case study, patients who ingested a higher dose of the drug over an 18-month period, saw a reduction in amyloid plaque in the brain; Unlike patients who took a higher dose of generic medication for the same number of months, 26%'s results slowly declined. As for the Anavex 2-73 case study, patients who were genetically compatible with the drug and took it for 57 weeks saw amazing results such as the patient communicated correctly, understood and performed their daily routines. Researchers, in both studies, demonstrated successful results with their patients in clinical trials. The clinical study of BAN2401 showed progress. According to James A. Hendrix, director of global scientific initiatives at the Alzheimer's Assn. States that "Alzheimer's disease trials must evolve", trying new things and learning more about other diseases such as cancer, approaching an effective therapeutic method to cure this disease. He also says he would like to make progress in diagnosing early symptoms before the disease manifests and in asymptomatic people. I agree with Hendrix's statement because his approach to expanding his research to explore other diseases such as curing cancer and wanting to advance his research to find an earlier approach to detect this disease brain destroyer is a wonderful idea. This will certainly have a global impact on our future and give hope to those who will be genetically affected by this disease. As for other precision drugs, Anavex 2-73 has also made progress. The author.